Extended Data Fig. 1: Stratifying glioma patients.
From: Amplifying mutational profiling of extracellular vesicle mRNA with SCOPE
(a) SCOPE analyzed plasma samples collected from radiologically confirmed glioma patients. Tissue samples were used for clinical pathology. (b) Target RNA sequences for glioma-SCOPE analyses. IDH1 probes were designed to detect wild-type (WT) and single nucleotide mutation (R132H), and EGFR probes to detect WT as well as the variant III (EGFRvIII) resulting from genomic deletion of exons 2–7 in the EGFR gene. (c) The specificity of glioma-SCOPE probes was evaluated. The designed probes achieved a high signal contrast (>30) between on-target and off-target samples. Synthetic RNA samples (1 nM) were used. The heatmap displays mean values from technical triplicate measurements. a.u., arbitrary unit. (d) Application of SCOPE to profile EVs for IDH1 (WT, R132H) and EGFR (WT, vIII). EVs were harvested from glioma cell lines. The results confirmed that EVs reflected the genotype of parent glioma cells. Data are shown as mean ± s.d. from biological triplicates. a.u., arbitrary unit. (e) Plasma EVs were analyzed via SCOPE for IDH1 (WT, R132H) and EGFR (WT, vIII). Control samples were from healthy donors (n = 15). Glioma samples were from patients with different genotypes: EGFR amplification (GBM-WT; n = 20), IDH1-R132H mutation (n = 20), and EGFRvIII mutation (n = 20). The SCOPE assay identified glioma patients and correctly stratified them according to their molecular genotypes. The heatmap shows mean values from technical triplicate measurements.
